The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma, according to the researchers.
Taking HIV patients off medications during periods when the disease appears to be under control is a risky – and sometimes fatal – treatment strategy, according to a large international study published in the New England Journal of Medicine.
A new study examined muscle strength, performance and outcomes perceived by patients several years after undergoing a meniscectomy.
Northwestern University is launching an experimental program for young women who may be at risk to lose their ovarian function and fertility following treatment for cancer. In the program, a woman’s ovary is removed and frozen for possible future use. The long-term goal is to be able to extract and mature eggs from cryopreserved (frozen) ovarian tissues to initiate pregnancies once cancer treatment has been completed. Thus far, pregnancies resulting from this research are in mice.
Results from one of the largest HIV/AIDS treatment trials ever conducted show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. In the study, the investigators used two predetermined levels of CD4+ T cells, the primary immune cell targeted by HIV, to guide them in respectively suspending or restarting the study participants on antiretroviral therapy.
People with auto-immune conditions like MS, arthritis and lupus can benefit from low impact aerobic exercise — including walking and cycling — that increases in intensity, duration and frequency. A review of studies between 1987 and 2006 shows that 12-week programmes that involved exercising for 30 to 60 minutes, three times a week, yielded the most effective results.
German researchers found using a minimally invasive technique to correct blocked vessels in the testicles i.e. varicoceles, one of the commonest causes of male infertility can increase the chances of fathering a child. The findings were presented at the annual meeting of the Radiological Society of North America.
?terna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today disclosed additional positive top line Phase 1 results for its cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers. Further data showed the compound?s good safety profile and established the maximum tolerated dose (MTD) at 267 mg/m? which will be the recommended dose for a Phase 2 trial. In addition to good safety data, the trial provided a hint of efficacy as disease stabilization and regression of lesions were observed at the 160 mg/m? and 267 mg/m? dose levels.
On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune (nevirapine) do not prevent access to this medication in low income countries.
Researchers at Harvard Medical School’s Brigham and Women’s Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients.